EP0482554A2 - Transdermal Drug Delivery Preparation - Google Patents
Transdermal Drug Delivery Preparation Download PDFInfo
- Publication number
- EP0482554A2 EP0482554A2 EP91117920A EP91117920A EP0482554A2 EP 0482554 A2 EP0482554 A2 EP 0482554A2 EP 91117920 A EP91117920 A EP 91117920A EP 91117920 A EP91117920 A EP 91117920A EP 0482554 A2 EP0482554 A2 EP 0482554A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- sticky composition
- composition according
- sticky
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
Definitions
- the present invention relates to a sticky composition for medical use and a transdermal drug delivery preparation incorporating it, more specifically to a sticky composition for medical use which causes little skin irritation and is hence safe and which has excellent adhesive properties and a transdermal drug delivery preparation for treating a diseased part of body or for delivering a drug to the circulatory system.
- plasters applied to the body to treat skin lesions or to transdermally deliver drugs to internal lesions or the circulatory system and other organs and other medical adhesives used in medical devices are prepared from polyvinyl alkyl ethers, poly(meth )acrylates, 2-ethylhexyl acrylate-2-ethylhexyl methacrylate copolymers, 2-ethylhexyl acrylate-vinylpyrrolidone copolymers, polyurethane, styrene-isoprene-styrene block copolymers, polyisobutylene rubber, polyisoprene rubber, butyl rubber, natural rubber, silicone resin and other substances.
- known tackifiers, softening agents, fillers, anti-aging agents and other additives are added.
- sticky compositions are required to be safe with little skin irritation and to have well-balanced adhesive properties (tack, adhesion, cohesion).
- sticky compositions based on acrylic resin are known to have skin irritancy causing skin sweating, flare or edema.
- Sticky compositions based on silicone resin are faulty in that the plaster is liable to detaching due to sweating or the plaster becomes more likely to be detached when it is attached to the joint.
- transdermal drug delivery preparations aiming at systemic action as well as action on skin lesions. These preparations have been increasingly recognized to be useful as sustained-release preparations.
- This kind of conventional transdermal drug delivery preparations includes those using a medical adhesive as an adhesive base comprising an adhesive polymer layer as described above which contains a drug and a release aid which promotes the release of the drug on a drug-impermeable backing material. By plastering them on the body, drugs are delivered to diseased parts of the body or to the circulatory system.
- the adhesive base for the transdermal drug delivery preparation is required to have high safety and well-balanced adhesive properties and offer good drug release. Particularly in transdermal drug delivery preparations aiming at systemic action, drug release from drug carrier is known to be a key factor.
- the silicone elastomer described above is widely used as a base for implantation preparations and transdermal drug delivery devices and as a drug carrier for various other preparations because it is very safe, it is known to have a problem in drug release in addition to the above-mentioned problems such as the tendency for plaster to be detached due to sweating when it is used as an adhesive base for transdermal drug delivery preparations.
- the releasing property for the drug retained by the silicone elastomer i.e., an active ingredient pharmaceutical compound
- the drug releasing property of silicone elastomer is usually very low; therefore, development of devices incorporating the silicone elastomer described above is limited to drugs whose effective dose is low like scopolamine.
- a sticky composition comprising a tackifier and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group, which can serve as a medical adhesive having excellent safety and adhesive properties.
- the present invention is based on the finding that the sticky composition for medical use of the present invention causes very little skin irritation and has excellent adhesive properties.
- transdermal drug delivery preparation of the present invention which comprises a mixture of a transdermally absorbable pharmaceutical compound as an active ingredient and an auxiliary agent in an elastomer of the sticky composition described above as a base which offers good release of the active ingredient drug.
- the present invention comprises the following:
- silicon-containing group used here examples include those represented by Formula II as in (1) above.
- Figure 1 shows the drug releases in a diffusion cell from the preparations obtained in Examples 4 through 6 and a control preparation.
- Figure 2 shows the time courses of drug concentration in rat blood for the preparations obtained in Examples 6 and 9 and a control preparation.
- oxyalkylene polymer having a silicon-containing group in the molecular structure for the present invention known polymers disclosed in Japanese Patent Examined Publication Nos. 36319/1970, 12154/1971 and 32673/1974, Japanese Patent Laid-Open Nos. 156599/1975, 73561/1976, 6096/1979, 82123/1980, 123620/1980, 125121/1980, 131022/1980, 135135/1980 and 137129/1980 and other publications can be used with no limitation.
- the molecular chain of the oxyalkylene polymer preferably has a repeat unit essentially represented by the formula I: -R1 -O- ( I ) wherein R1 represents a divalent organic group, with most preference given to the case where the majority of R1 is a hydrocarbon group having 3 or 4 carbon atoms.
- R1 include the following: The following compound is most preferable from the viewpoint of adhesive properties.
- the molecular chain of the oxyalkylene polymer described above may comprise only one kind of repeat unit or two or more kinds of repeat units.
- the repeat unit represented by the formula -R1-O- is contained in the polymer at normally over 50% (% by weight, the same applies below), preferably over 70%, and even more preferably over 80%.
- the silicon-containing group for the present invention is a well known functional group. Typical examples thereof include the group represented by the formula II: wherein X represents an hydroxyl group or hydrolyzable group; when there are two or more X groups, they may be identical or not; R2 represents a monovalent hydrocarbon group having 1 to 20 carbon atoms or a triorganosiloxy group represented by (R')3SiO- (R' represents a monovalent hydrocarbon group having 1 to 20 carbon atoms; the three R' groups may be identical or not); when there are two or more R2 groups, they may be identical or not; a represents 0, 1, 2 or 3; b represents 0, 1 or 2; 1 ⁇ a + mb, wherein m represents 0 or an integer of 1 to 19, and when m is 2 or more, the b numbers may not be identical.
- the silicon-containing group described above is preferably a group wherein m is 0 and which is represented by the formula III: wherein R2 and X have the same definition as above; n represents 1 2 or 3.
- hydrolyzable group in Formula II examples include a halogen atom, hydrogen atom, alkoxy group, acyloxy group, ketoximate group, amino group, amide group, aminooxy group, mercapto group and alkenyloxy group, with preference given to an alkoxy group such as a methoxy group or ethoxy group, since they will undergo mild hydrolysis.
- Examples of the hydrocarbon group having 1 to 20 carbon atoms for R2 in Formula II and of the monovalent hydrocarbon group having 1 to 20 carbon atoms for R' in (R')3SiO- include alkyl groups such as the methyl group and ethyl group, cycloalkyl groups such as the cyclohexyl group, aryl groups such as the phenyl group and aralkyl groups such as the benzyl group, with preference given to the methyl group from the viewpoint of reactivity.
- the number of silicon-containing groups in the oxyalkylene polymer is normally not less than 1, preferably not less than 1.1, and still more preferably not less than 1.5 on average.
- the silicon-containing group may be located on a side chain of the molecular chain of the oxyalkylene polymer, it is preferably present in a terminal.
- the number-average molecular weight of the oxyalkylene polymer is normally 500 to 30000, preferably 3000 to 15000, and still more preferably 5000 to 10000.
- the oxyalkylene polymer may be used singly or in combination of two or more kinds.
- the oxyalkylene polymer for the present invention may be one of the known ones proposed in various publications as stated above. Therefore, these oxyalkylene polymers can easily be prepared by known methods disclosed in these known publications. Examples thereof include MS Polymer 20A (functional group: -SiCH3(OCH3)2 , number-average molecular weight: 7500), MS Polymer # 300 (functional group: -SiCH3(OCH3)2 , number-average molecular weight: 8500), SILYL 5A01 (functional group: -SiCH3(OCH3)2, number-average molecular weight: 8500), SILYL 5B25 (functional group: -SiCH3(OCH3)2 , -NH2, number-average molecular weight: 8000), SILYL 5B30 (functional group: -SiCH3(OCH3)2, -NH2, number-average molecular weight: 5000), produced by Kanegafuchi Chemical Industry Co., Ltd..
- the sticky composition of the present invention contains normally 10 to 140 parts by weight of a compatible tackifier resin and 1 to 30 parts by weight of a setting catalyst, relative to 100 parts by weight of the oxyalkylene polymer.
- the amounts of tackifier resin below 10 parts by weight or above 140 parts by weight are undesirable because the adhesion is insufficient in the former case and no desired effect is obtained in proportion to the amount added and paste retention can occur on the subject of plastering in the latter case.
- the tackifier resin is not subject to limitation, as long as it is compatible with the oxyalkylene polymer for the present invention.
- Known tackifier resins can be used, such as rosin resins (rosin, rosin ester, hydrogenated rosin), phenol resins, terpene phenol resins, xylene resins, aliphatic petroleum resins, aromatic petroleum resins, terpene resins and cumarone resins, with preference given to rosin ester resins and terpene phenol resins.
- amines such as dibutylamine-2-ethylhexoate and other acidic or alkaline catalysts can be used, with preference given to aluminum based catalysts such as aluminum chelate and aluminum alcoholate.
- anti-aging agent known substances such as BHT (benzenehydroxytoluene) and vitamin E can be used. Also, these sticky compositions may be formulated with other known bases etc. for various purposes.
- the sticky composition for medical use of the present invention can be prepared by dissolving an oxyalkylene polymer, tackifier resin, setting catalyst, anti-aging agent and other additives as described above in a solvent such as isopropyl alcohol, ethanol, methanol, acetone, toluene or ethyl acetate.
- a solvent such as isopropyl alcohol, ethanol, methanol, acetone, toluene or ethyl acetate.
- the solvent is not subject to limitation, it is preferable to use ethanol, isopropyl alcohol or the like from the viewpoint of safety.
- the sticky composition thus obtained can be used for medical use in plaster, adhesive sheet and other forms by conventional methods.
- the sticky composition can be used as a drug carrier in the transdermal drug delivery preparation of the present invention.
- the skin irritancy of the sticky composition for medical use of the present invention is very low.
- the oxyalkylene polymer itself was tested for irritancy. It was found non-irritative, whose PCI (primary cutaneous irritation index) was 0 as determined by a primary skin irritation test in rabbits (Draize's method, 1959, FDA). Even when the tackifier resin, setting catalyst, anti-aging agent and other bases described above were added to the oxyalkylene polymer to yield a sticky composition, the PCI of the sticky composition was close to about 1.
- the sticky composition for medical use of the present invention can be judged to have very low skin irritancy.
- sticky compositions for medical use are usually required to have sufficient vapor permeability and oxygen permeability, moderate flexibility, good stability to heat and light and well-balanced adhesive properties without involving deterioration of the sticky composition or adhesion failure between the sticky composition layer and the backing material.
- the sticky composition for medical use of the present invention meets all these requirements for properties and has sufficient vapor permeability, the plaster does not become detached from skin due to sweating.
- the transdermal drug delivery preparation of the present invention is characterized by the use of the sticky composition for medical use of the present invention described above as a drug carrier.
- the drug for the present invention i.e., a pharmaceutical compound as an active ingredient, is not subject to limitation, as long as it is transdermally absorbable. Examples of such compounds include the following:
- These drugs may be used in combination of two or more kinds as necessary.
- the transdermal drug delivery preparation of the present invention can be prepared as follows.
- a drug i.e., a pharmaceutical compound as an active ingredient, is normally uniformly mixed in alcohol along with an auxiliary agent to yield a pasty or dissolved mixture.
- the auxiliary agent is used as necessary.
- plasticizers such as liquid silicone, absorption promoters such as isopropyl myristate, azone, urea, glycerol, monoglyceride and diisopropyl adipate and fillers such as silica, potassium carbonate, kaolin and talc.
- alcohols which are normally used as solvents include isopropyl alcohol, methanol, ethanol and butanol, with preference given to isopropyl alcohol and ethanol from the viewpoint of safety.
- the resulting dissolved or pasty mixture is uniformly mixed in the sticky composition described above to dissolve or disperse as fine powder.
- a setting catalyst When the sticky composition has been formulated with a setting catalyst, it is placed in an appropriate mold and set and formed at room temperature or increased temperature to yield the transdermal drug delivery preparation of the present invention.
- a setting catalyst is appropriately added to the mixture and thoroughly mixed quickly, after which the mixture is placed in an appropriate mold and set and formed at room temperature or increased temperature to yield the transdermal drug delivery preparation of the present invention.
- the transdermal drug delivery preparation of the present invention is preferably prepared to a composition of 0.05 to 40 parts by weight of pharmaceutical compound, 1 to 30 parts by weight of auxiliary agent and 30 to 90 parts by weight of sticky composition, though the content of the pharmaceutical compound in the finished preparation varies depending on the kind of the drug used, i.e., the pharmaceutical compound as an active ingredient and the kind of target disease.
- the transdermal drug delivery preparation thus obtained comprises the sticky composition of the present invention described above as a drug carrier and offers excellent drug release.
- the transdermal drug delivery preparation of the present invention offers quicker and more release in comparison with conventional preparations incorporating a silicone elastomer.
- transdermal drug delivery preparation of the present invention is used in accordance with ordinary methods, though dosage, administration frequency and other factors vary depending on the kind of the drug used, i.e., the pharmaceutical compound as an active ingredient and the kind of target disease.
- the sticky composition for medical use of the present invention possesses excellent adhesive properties, very low skin irritancy and good compatibility with the site of plastering and thus serves as a very safe and effective medical adhesive.
- This sticky composition for medical use can be used for artificial anus, medical tapes, prevention of bedsores, attaching medical devices or their terminals to the human body and other purposes as well as for percutaneous and permucosal administration.
- the transdermal drug delivery preparation of the present invention offers excellent drug release from the sticky composition of the invention, which is a drug carrier. Therefore, the transdermal drug delivery preparation of the present invention allows absorption of a sufficient amount of drug via skin, which is thus easy to apply and permits a high level of drug concentration in blood.
- the oxyalkylene polymer for the present invention having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group, can be prepared as follows. First, 320 g of a polyoxypropylene glycol having an average molecular weight of 3200 (of the total terminal group content, allyl ether groups account for 15%, propenyl ether groups account for 3% and hydroxyl groups account for 82%) were charged into a nitrogen-substituted 1-liter pressure-resistant reactor equipped with a stirring rod. Subsequently, 40.8 g of powdered caustic soda (purity 98%) were added, and the temperature was raised to 60 °C.
- the terminal groups of the polymer were 90% of allyl ether groups, 8% of propenyl ether groups and 2% of hydroxyl groups.
- 84 g of the polymer obtained on a 500-ml pressure-resistant reactor equipped with a stirring rod were taken.
- 0.05 ml a of catalyst solution of chloroplatinic acid (2 g of H2PtCl6 ⁇ 6H2O were dissolved in 20 ml of isopropanol and 78 ml of tetrahydrofuran) and 2.1 g of methyl dimethoxysilane were added, followed by 8 hours of reaction at 100°C.
- the volatile substances were evaporated off to yield an alkylene oxide polymer wherein the group represented by the following formula accounts for 82% of the terminal groups.
- an oxyalkylene polymer (SILYL 5A01, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 8500 and a terminal silicon-containing group represented by -SiCH3(OCH3)2, 80 parts by weight of rosin ester (ester gum AAG, produced by Arakawa Kagaku) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol.
- the sticky composition polymer was coated and dried on a polyethylene film of 80 ⁇ m in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 ⁇ m to yield an adhesive plaster.
- an oxyalkylene polymer (SILYL 5A01, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 8500 and a terminal silicon-containing group represented by -SiCH3(OCH3)2, 40 parts by weight of terpene phenol resin (YS Polyster S145, produced by Yasuhara Chemical) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol.
- the sticky composition polymer was coated and dried on a polyethylene film of 80 ⁇ m in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 ⁇ m to yield an adhesive plaster.
- an oxyalkylene polymer (MS polymer 20A, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 7500 and a terminal silicon-containing group represented by -SiCH3(OCH3)2, 80 parts by weight of rosin ester (ester gum AAG, produced by Arakawa Kagaku) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol.
- the sticky composition polymer was coated and dried on a polyethylene film of 80 ⁇ m in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 ⁇ m to yield an adhesive plaster.
- testosterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- estradiol as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- testosterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- progesterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- estradiol as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- the sample had a totally milky white, uniform adhesive layer immediately after preparation, which appearance remained unchanged even after 60 days of storage at room temperature and after 60 days of storage in aluminum foil package at 40°C.
- Tack value J. Dow's method, JIS Z 0237 was about 20 immediately after preparation, which remained unchanged even after storage. Good adhesive properties were noted.
- the silicone elastomer used was a product of Dow Corning (Dow Corning® 2920 Medical Adhesive), to which testosterone, progesterone or estradiol was added to reach a concentration of 2.5 wt%, followed by setting and forming. For this test, each sample was made to have a film thickness of 50 ⁇ m. After loading on a vertical diffusion cell produced by Crown-Glas Company, each sample was tested for drug release in a saline containing 40% polyethylene glycol 400 as a elution solvent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to a sticky composition for medical use and a transdermal drug delivery preparation incorporating it, more specifically to a sticky composition for medical use which causes little skin irritation and is hence safe and which has excellent adhesive properties and a transdermal drug delivery preparation for treating a diseased part of body or for delivering a drug to the circulatory system.
- Traditionally, plasters applied to the body to treat skin lesions or to transdermally deliver drugs to internal lesions or the circulatory system and other organs and other medical adhesives used in medical devices are prepared from polyvinyl alkyl ethers, poly(meth )acrylates, 2-ethylhexyl acrylate-2-ethylhexyl methacrylate copolymers, 2-ethylhexyl acrylate-vinylpyrrolidone copolymers, polyurethane, styrene-isoprene-styrene block copolymers, polyisobutylene rubber, polyisoprene rubber, butyl rubber, natural rubber, silicone resin and other substances. To give a pressure-sensitive adhesion property to these copolymers, known tackifiers, softening agents, fillers, anti-aging agents and other additives are added.
- These sticky compositions are required to be safe with little skin irritation and to have well-balanced adhesive properties (tack, adhesion, cohesion). However, none of them meets all these requirements. For example, sticky compositions based on acrylic resin are known to have skin irritancy causing skin sweating, flare or edema. Sticky compositions based on silicone resin are faulty in that the plaster is liable to detaching due to sweating or the plaster becomes more likely to be detached when it is attached to the joint.
- In recent years, there has been remarkable progress based on the concept of drug delivery system in the development of transdermal drug delivery preparations aiming at systemic action as well as action on skin lesions. These preparations have been increasingly recognized to be useful as sustained-release preparations. This kind of conventional transdermal drug delivery preparations includes those using a medical adhesive as an adhesive base comprising an adhesive polymer layer as described above which contains a drug and a release aid which promotes the release of the drug on a drug-impermeable backing material. By plastering them on the body, drugs are delivered to diseased parts of the body or to the circulatory system.
- The adhesive base for the transdermal drug delivery preparation is required to have high safety and well-balanced adhesive properties and offer good drug release. Particularly in transdermal drug delivery preparations aiming at systemic action, drug release from drug carrier is known to be a key factor. Although the silicone elastomer described above is widely used as a base for implantation preparations and transdermal drug delivery devices and as a drug carrier for various other preparations because it is very safe, it is known to have a problem in drug release in addition to the above-mentioned problems such as the tendency for plaster to be detached due to sweating when it is used as an adhesive base for transdermal drug delivery preparations. In transdermal drug delivery preparations incorporating a silicone elastomer as an adhesive polymer layer, i.e., an adhesive base, the releasing property for the drug retained by the silicone elastomer, i.e., an active ingredient pharmaceutical compound, is very high, provided that the drug has an extremely high vapor pressure like nitroglycerin; and very useful products of devices have been developed. However, the drug releasing property of silicone elastomer is usually very low; therefore, development of devices incorporating the silicone elastomer described above is limited to drugs whose effective dose is low like scopolamine.
- It is an object of the present invention to provide a sticky composition for medical use which causes very little skin irritation and which has excellent adhesive properties and good compatibility with the site of plastering.
- It is another object of the invention to provide a transdermal drug delivery preparation which is very safe and which offers good drug release.
- The solution to the problems described above is a sticky composition comprising a tackifier and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group, which can serve as a medical adhesive having excellent safety and adhesive properties.
- Accordingly, the present invention is based on the finding that the sticky composition for medical use of the present invention causes very little skin irritation and has excellent adhesive properties.
- The inventor made further investigations to overcome the drawbacks of conventional transdermal drug delivery preparations and developed the transdermal drug delivery preparation of the present invention, which comprises a mixture of a transdermally absorbable pharmaceutical compound as an active ingredient and an auxiliary agent in an elastomer of the sticky composition described above as a base which offers good release of the active ingredient drug.
- Accordingly, the present invention comprises the following:
- (1) A sticky composition for medical use comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group.
Examples of the silicon-containing group include those represented by the formula II: - (2) A transdermal drug delivery preparation incorporating as a drug carrier a sticky composition comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group.
- Examples of the silicon-containing group used here include those represented by Formula II as in (1) above.
- Figure 1 shows the drug releases in a diffusion cell from the preparations obtained in Examples 4 through 6 and a control preparation.
- Figure 2 shows the time courses of drug concentration in rat blood for the preparations obtained in Examples 6 and 9 and a control preparation.
- As an oxyalkylene polymer having a silicon-containing group in the molecular structure for the present invention, known polymers disclosed in Japanese Patent Examined Publication Nos. 36319/1970, 12154/1971 and 32673/1974, Japanese Patent Laid-Open Nos. 156599/1975, 73561/1976, 6096/1979, 82123/1980, 123620/1980, 125121/1980, 131022/1980, 135135/1980 and 137129/1980 and other publications can be used with no limitation.
- The molecular chain of the oxyalkylene polymer preferably has a repeat unit essentially represented by the formula I:
-R¹ -O- ( I )
wherein R¹ represents a divalent organic group, with most preference given to the case where the majority of R¹ is a hydrocarbon group having 3 or 4 carbon atoms. Examples of R¹ include the following:
The following compound is most preferable from the viewpoint of adhesive properties. - The molecular chain of the oxyalkylene polymer described above may comprise only one kind of repeat unit or two or more kinds of repeat units.
- The repeat unit represented by the formula -R¹-O- is contained in the polymer at normally over 50% (% by weight, the same applies below), preferably over 70%, and even more preferably over 80%.
- The silicon-containing group for the present invention is a well known functional group. Typical examples thereof include the group represented by the formula II:
wherein X represents an hydroxyl group or hydrolyzable group; when there are two or more X groups, they may be identical or not; R² represents a monovalent hydrocarbon group having 1 to 20 carbon atoms or a triorganosiloxy group represented by (R')₃SiO- (R' represents a monovalent hydrocarbon group having 1 to 20 carbon atoms; the three R' groups may be identical or not); when there are two or more R² groups, they may be identical or not; a represents 0, 1, 2 or 3; b represents 0, 1 or 2; 1 ≦ a + mb, wherein m represents 0 or an integer of 1 to 19, and when m is 2 or more, the b numbers may not be identical. -
- Examples of the hydrolyzable group in Formula II include a halogen atom, hydrogen atom, alkoxy group, acyloxy group, ketoximate group, amino group, amide group, aminooxy group, mercapto group and alkenyloxy group, with preference given to an alkoxy group such as a methoxy group or ethoxy group, since they will undergo mild hydrolysis.
- Examples of the hydrocarbon group having 1 to 20 carbon atoms for R² in Formula II and of the monovalent hydrocarbon group having 1 to 20 carbon atoms for R' in (R')₃SiO- include alkyl groups such as the methyl group and ethyl group, cycloalkyl groups such as the cyclohexyl group, aryl groups such as the phenyl group and aralkyl groups such as the benzyl group, with preference given to the methyl group from the viewpoint of reactivity.
- For sufficient hardening, the number of silicon-containing groups in the oxyalkylene polymer is normally not less than 1, preferably not less than 1.1, and still more preferably not less than 1.5 on average.
- Although the silicon-containing group may be located on a side chain of the molecular chain of the oxyalkylene polymer, it is preferably present in a terminal. The number-average molecular weight of the oxyalkylene polymer is normally 500 to 30000, preferably 3000 to 15000, and still more preferably 5000 to 10000.
- The oxyalkylene polymer may be used singly or in combination of two or more kinds.
- The oxyalkylene polymer for the present invention may be one of the known ones proposed in various publications as stated above. Therefore, these oxyalkylene polymers can easily be prepared by known methods disclosed in these known publications. Examples thereof include MS Polymer 20A (functional group: -SiCH₃(OCH₃)₂ , number-average molecular weight: 7500), MS Polymer # 300 (functional group: -SiCH₃(OCH₃)₂ , number-average molecular weight: 8500), SILYL 5A01 (functional group: -SiCH₃(OCH₃)₂, number-average molecular weight: 8500), SILYL 5B25 (functional group: -SiCH₃(OCH₃)₂ , -NH₂, number-average molecular weight: 8000), SILYL 5B30 (functional group: -SiCH₃(OCH₃)₂, -NH₂, number-average molecular weight: 5000), produced by Kanegafuchi Chemical Industry Co., Ltd..
- The sticky composition of the present invention contains normally 10 to 140 parts by weight of a compatible tackifier resin and 1 to 30 parts by weight of a setting catalyst, relative to 100 parts by weight of the oxyalkylene polymer. The amounts of tackifier resin below 10 parts by weight or above 140 parts by weight are undesirable because the adhesion is insufficient in the former case and no desired effect is obtained in proportion to the amount added and paste retention can occur on the subject of plastering in the latter case.
- The tackifier resin is not subject to limitation, as long as it is compatible with the oxyalkylene polymer for the present invention. Known tackifier resins can be used, such as rosin resins (rosin, rosin ester, hydrogenated rosin), phenol resins, terpene phenol resins, xylene resins, aliphatic petroleum resins, aromatic petroleum resins, terpene resins and cumarone resins, with preference given to rosin ester resins and terpene phenol resins.
- As setting catalysts, known tin or aluminum based catalysts, amines such as dibutylamine-2-ethylhexoate and other acidic or alkaline catalysts can be used, with preference given to aluminum based catalysts such as aluminum chelate and aluminum alcoholate. As anti-aging agent, known substances such as BHT (benzenehydroxytoluene) and vitamin E can be used. Also, these sticky compositions may be formulated with other known bases etc. for various purposes.
- The sticky composition for medical use of the present invention can be prepared by dissolving an oxyalkylene polymer, tackifier resin, setting catalyst, anti-aging agent and other additives as described above in a solvent such as isopropyl alcohol, ethanol, methanol, acetone, toluene or ethyl acetate. The preparation thus obtained can be used as a sticky composition after the process of coating, forming and setting, for instance.
- Although the solvent is not subject to limitation, it is preferable to use ethanol, isopropyl alcohol or the like from the viewpoint of safety. The sticky composition thus obtained can be used for medical use in plaster, adhesive sheet and other forms by conventional methods. Particularly, the sticky composition can be used as a drug carrier in the transdermal drug delivery preparation of the present invention.
- The skin irritancy of the sticky composition for medical use of the present invention is very low. To confirm this, the oxyalkylene polymer itself was tested for irritancy. It was found non-irritative, whose PCI (primary cutaneous irritation index) was 0 as determined by a primary skin irritation test in rabbits (Draize's method, 1959, FDA). Even when the tackifier resin, setting catalyst, anti-aging agent and other bases described above were added to the oxyalkylene polymer to yield a sticky composition, the PCI of the sticky composition was close to about 1. Since the PCI classification comprises three grades of "weak irritant" for
scores 0 to 2, "moderate irritant" for 3 to 5 and "strong irritant" for 6 to 8, the sticky composition for medical use of the present invention can be judged to have very low skin irritancy. - With respect to properties other than the skin irritancy, sticky compositions for medical use are usually required to have sufficient vapor permeability and oxygen permeability, moderate flexibility, good stability to heat and light and well-balanced adhesive properties without involving deterioration of the sticky composition or adhesion failure between the sticky composition layer and the backing material.
- Since the sticky composition for medical use of the present invention meets all these requirements for properties and has sufficient vapor permeability, the plaster does not become detached from skin due to sweating.
- The transdermal drug delivery preparation of the present invention is characterized by the use of the sticky composition for medical use of the present invention described above as a drug carrier. The drug for the present invention, i.e., a pharmaceutical compound as an active ingredient, is not subject to limitation, as long as it is transdermally absorbable. Examples of such compounds include the following:
- a) Antibiotics such as penicillins, cephalosporins, erythromycins, tetracyclines, macrolides, aminoglycosides, fosfomycins and rifampicins.
- b) Antipyretics, analgesics and anti-inflammatory drugs such as mefenamic acid, flufenamic acid, indometacin, diclofenac, acetaminophen, alclofenac, oxyphenbutazone, phenylbutazone, ibuprofen, ketoprofen, salicylic acid, methyl salicylate, L-menthol, camphor, sulindac, naproxen, fenbufen, aspirin, sulpyrine, tiaramide hydrochloride and piroxicam.
- c) Antihistaminics such as α -chlorpheniramine maleate, diphenylpyraline, diphenhydramine, clemastine fumarate and promethazine hydrochloride.
- d) Psychotropic drugs for hypnosis, sedation and ataraxia such as diazepam, chlorpromazine hydrochloride, chlordiazepoxide, sulpiride, haloperidol, ethyl loflazepate, fluphenazine, thioridazine, fludiazepam, flunitrazepam, phenobarbital, amobarbital, cyclobarbital, triazolam and nitrazepam.
- e) Coronary vasodilators such as nitroglycerin, isosorbide dinitrate, nitroglycol, erythritol tetranitrate, pentaerythritol tetranitrate, verapamyl (hydrochloride), nifedipine, dipyridamole and diltiazem hydrochloride.
- f) Antiarrhythmics and antihypertensive drugs such as propranolol (hydrochloride), pindolol, clonidine (hydrochloride), bupranolol, indenolol, nilvadipine, nipradilol, bucumolol, hydrazine hydrochloride and rescinnamine.
- g) Hypotensive diuretics such as hydrothiazide, benzylhydrochlorothiazide and cyclopenthiazide and diuretics such as furosemide, mefruside, trichlormethiazide and thiobromine.
- h) Chemotherapeutic drugs such as aciclovir, nalidixic acid and sulfa drugs.
- i) Anticancer agents such as 5-FU, vincristine, adriamycin, bleomycin, mitomycin, cisplatin and therarubicin.
- j) Antiemetics agents such as metoclopramide, clebopride, scopolamine (hydrobromide) and domperidone.
- k) Vitamins such as vitamin A, vitamin E, vitamin K, ergocalciferol, cholecalciferol, octotiamine and riboflavin tetrabutyrate.
- l) Antispasmodics such as nitrazepam, clonazepam, baclofen and meprobamate.
- m) Antitussives such as dextromethorphane, terbutaline (sulfate), ephedrine (hydrochloride), salbutamol (hemisulfate), isoproterenol and trimetoquinol hydrochloride.
- n) Cardiacs such as prenylamine lactate, digitoxin and digoxin.
- o) Anesthetics such as lidocaine, benzocaine and ethyl-p-aminobenzoate.
- p) Cerebrovascular improvers such as Hydergine, ergot alkaloid and ifenprodil.
- q) Antifungal drugs such as pentamycin, amphotericin B, pyrrolnitrin, clotrimazole, benzalkonium chloride, nitrofurazone, nystatin and acetosulfamine.
- r) Steroids such as hydrocortisone, prednisolone, paramethasone, beclomethasone dipropionate, flumethasone, betamethasone, betamethasone valerate, dexamethasone, triamcinolone, triamcinolone acetonide, fluocinolone, fluocinolone acetonide, clobetasol propionate, progesterone, testosterone and estradiol.
- s) Anti-parkinsonism drugs such as L-dopa, bromocriptine mesilate, trihexyphenidyl hydrochloride, mazaticol hydrochloride and biperiden hydrochloride.
- t) Biologics such as TRH, LHRH, TNF, lymphotoxin, interferon, urokinase, insulin, calcitonin, their derivative polypeptides and prostaglandins.
- u) Others such as tolbutamide and other antidiabetic drugs, colchicine and other anti-gout drugs and nicotine and other smoking suppressors.
- These drugs may be used in combination of two or more kinds as necessary.
- The transdermal drug delivery preparation of the present invention can be prepared as follows. A drug, i.e., a pharmaceutical compound as an active ingredient, is normally uniformly mixed in alcohol along with an auxiliary agent to yield a pasty or dissolved mixture. The auxiliary agent is used as necessary. Examples thereof include plasticizers such as liquid silicone, absorption promoters such as isopropyl myristate, azone, urea, glycerol, monoglyceride and diisopropyl adipate and fillers such as silica, potassium carbonate, kaolin and talc.
- Examples of alcohols which are normally used as solvents include isopropyl alcohol, methanol, ethanol and butanol, with preference given to isopropyl alcohol and ethanol from the viewpoint of safety.
- The resulting dissolved or pasty mixture is uniformly mixed in the sticky composition described above to dissolve or disperse as fine powder. When the sticky composition has been formulated with a setting catalyst, it is placed in an appropriate mold and set and formed at room temperature or increased temperature to yield the transdermal drug delivery preparation of the present invention. When the sticky composition has not been formulated with a setting catalyst, a setting catalyst is appropriately added to the mixture and thoroughly mixed quickly, after which the mixture is placed in an appropriate mold and set and formed at room temperature or increased temperature to yield the transdermal drug delivery preparation of the present invention.
- The transdermal drug delivery preparation of the present invention is preferably prepared to a composition of 0.05 to 40 parts by weight of pharmaceutical compound, 1 to 30 parts by weight of auxiliary agent and 30 to 90 parts by weight of sticky composition, though the content of the pharmaceutical compound in the finished preparation varies depending on the kind of the drug used, i.e., the pharmaceutical compound as an active ingredient and the kind of target disease.
- The transdermal drug delivery preparation thus obtained comprises the sticky composition of the present invention described above as a drug carrier and offers excellent drug release.
- Various experimental models for drug release are known. For example, in drug release experiments using a diffusion cell, the transdermal drug delivery preparation of the present invention offers quicker and more release in comparison with conventional preparations incorporating a silicone elastomer.
- The transdermal drug delivery preparation of the present invention is used in accordance with ordinary methods, though dosage, administration frequency and other factors vary depending on the kind of the drug used, i.e., the pharmaceutical compound as an active ingredient and the kind of target disease.
- As stated above, the sticky composition for medical use of the present invention possesses excellent adhesive properties, very low skin irritancy and good compatibility with the site of plastering and thus serves as a very safe and effective medical adhesive. This sticky composition for medical use can be used for artificial anus, medical tapes, prevention of bedsores, attaching medical devices or their terminals to the human body and other purposes as well as for percutaneous and permucosal administration.
- Incorporating an oxyalkylene polymer, the transdermal drug delivery preparation of the present invention offers excellent drug release from the sticky composition of the invention, which is a drug carrier. Therefore, the transdermal drug delivery preparation of the present invention allows absorption of a sufficient amount of drug via skin, which is thus easy to apply and permits a high level of drug concentration in blood.
- The present invention is hereinafter described in more detail by means of the following working examples and test examples, but the invention is not limited by these examples and affords various applications, as long as they are not deviated from the technical scope of the invention.
- The oxyalkylene polymer for the present invention, having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group, can be prepared as follows. First, 320 g of a polyoxypropylene glycol having an average molecular weight of 3200 (of the total terminal group content, allyl ether groups account for 15%, propenyl ether groups account for 3% and hydroxyl groups account for 82%) were charged into a nitrogen-substituted 1-liter pressure-resistant reactor equipped with a stirring rod. Subsequently, 40.8 g of powdered caustic soda (purity 98%) were added, and the temperature was raised to 60 °C. Then, 7.76 g of bromochloromethane were added, followed by 10 hours of reaction at 60°C. Subsequently, the temperature in the reaction part was reduced to 50 °C, and 9.2 g of allyl chloride were added, followed by 10 hours of reaction at 50 °C. After completion of the reaction, the reaction product was transferred to a beaker, diluted with 1000 g of normal hexane and then treated with 50 g of aluminum silicate at normal temperature for 1 hour while stirring. After filtration, the resulting cake was washed with normal hexane several times. The volatile substances were evaporated off from the filtrate to yield 300 g of a propylene oxide polymer having an average molecular weight of 8000. The terminal groups of the polymer were 90% of allyl ether groups, 8% of propenyl ether groups and 2% of hydroxyl groups. 84 g of the polymer obtained on a 500-ml pressure-resistant reactor equipped with a stirring rod were taken. 0.05 ml a of catalyst solution of chloroplatinic acid (2 g of H₂PtCl₆ · 6H₂O were dissolved in 20 ml of isopropanol and 78 ml of tetrahydrofuran) and 2.1 g of methyl dimethoxysilane were added, followed by 8 hours of reaction at 100°C. Then, the volatile substances were evaporated off to yield an alkylene oxide polymer wherein the group represented by the following formula accounts for 82% of the terminal groups.
- To 100 parts by weight of an oxyalkylene polymer (SILYL 5A01, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 8500 and a terminal silicon-containing group represented by -SiCH₃(OCH₃)₂, 80 parts by weight of rosin ester (ester gum AAG, produced by Arakawa Kagaku) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol. The sticky composition polymer was coated and dried on a polyethylene film of 80 µm in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 µm to yield an adhesive plaster.
- To 100 parts by weight of an oxyalkylene polymer (SILYL 5A01, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 8500 and a terminal silicon-containing group represented by -SiCH₃(OCH₃)₂, 40 parts by weight of terpene phenol resin (YS Polyster S145, produced by Yasuhara Chemical) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol. The sticky composition polymer was coated and dried on a polyethylene film of 80 µm in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 µm to yield an adhesive plaster.
- To 100 parts by weight of an oxyalkylene polymer (MS polymer 20A, produced by Kanegafuchi Chemical Industry Co., Ltd.), which has a molecular weight of 7500 and a terminal silicon-containing group represented by -SiCH₃(OCH₃)₂, 80 parts by weight of rosin ester (ester gum AAG, produced by Arakawa Kagaku) as a tackifier resin, 10 parts by weight of a setting catalyst (aluminum chelate ALCH, produced by Kawaken Fine Chemical) and 0.5 part by weight of an anti-aging agent BHT were added, and a sticky composition polymer was prepared using isopropyl alcohol. The sticky composition polymer was coated and dried on a polyethylene film of 80 µm in thickness subjected to corona discharge treatment on one face to a dry film thickness of 50 µm to yield an adhesive plaster.
- To the sticky composition polymer prepared in Example 1, testosterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- To the sticky composition polymer prepared in Example 1, progesterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- To the sticky composition polymer prepared in Example 1, estradiol as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- To the sticky composition polymer prepared in Example 3, testosterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- To the sticky composition polymer prepared in Example 3, progesterone as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- To the sticky composition polymer prepared in Example 3, estradiol as a drug was added to a concentration of 2.5 wt%, followed by setting and forming to yield the transdermal drug delivery preparation of the present invention.
- With respect to the adhesive plasters prepared in Examples 1, 2 and 3, appearance, finger stickiness and tack value were examined immediately after preparation, after storage at room temperature for 60 days and after storage in aluminum foil package at 40°C for 60 days.
- For changes in appearance, the sample had a totally milky white, uniform adhesive layer immediately after preparation, which appearance remained unchanged even after 60 days of storage at room temperature and after 60 days of storage in aluminum foil package at 40°C.
- As for finger stickiness, good results were obtained immediately after preparation and after storage.
- Tack value (J. Dow's method, JIS Z 0237) was about 20 immediately after preparation, which remained unchanged even after storage. Good adhesive properties were noted.
- With respect to the adhesive plasters prepared in Examples 1, 2 and 3, 1 cm x 1 cm test pieces cut from the adhesive plasters immediately after preparation and after 60 days of storage at room temperature, respectively, were simultaneously plastered to the upper arm of 10 subjects, and changes in the adhesion condition was monitored for 24 hours.
- Good results were obtained with all 10 subjects; none of the test pieces became detached after 24 hours. Skin compatibility during plastering was good.
- With respect to the adhesive plasters prepared in Examples 1, 2 and 3, 2.5 cm x 2.5 cm test pieces cut from the adhesive plasters immediately after preparation and after 60 days of storage at room temperature, respectively, were simultaneously plastered to the upper arm of 10 subjects, and the plasters were removed after 24 hours. Within 30 to 60 minutes after removal, the plastering site was visually examined for the degree of erythema. Nothing more than very slight erythema was observed.
- Drug release from each of the testosterone, progesterone and estradiol preparations obtained in Examples 4 through 9 was compared with drug release from each of testosterone, progesterone and estradiol preparations prepared using a silicone elastomer.
- The silicone elastomer used was a product of Dow Corning (Dow Corning® 2920 Medical Adhesive), to which testosterone, progesterone or estradiol was added to reach a concentration of 2.5 wt%, followed by setting and forming. For this test, each sample was made to have a film thickness of 50 µm. After loading on a vertical diffusion cell produced by Crown-Glas Company, each sample was tested for drug release in a saline containing 40% polyethylene glycol 400 as a elution solvent.
- Cumulative release of testosterone, progesterone or estradiol was determined by HPLC on a time basis. HPLC determinations were made using a
Cosmosil 5 CN-R column (4.6 mm x 150 mm) at a flow rate of 1.0 ml/min in a CH₃OH/H₂O (40/60) solvent system for testosterone, progesterone or estradiol. - The results are shown in Figure 1. From Figure 1, it is evident that drug release from the preparations obtained in Examples 4 though 6 was better than that from the control preparation incorporating a silicone elastomer. The same tendency was noted in the preparations obtained in Examples 7 through 9 (data is not given in Figure 1). In the transdermal drug delivery preparation of the present invention, drug release from the sticky composition as a drug carrier is extremely higher than that obtained by using the control silicone elastomer.
- Male rats at 7 weeks of age with their hair clipped using electric clippers were subjected to plastering of the estradiol preparation of Example 6 or 9 or a control estradiol preparation incorporating the same silicone elastomer as used in Test Example 4 in the form of a 5 cm² piece (n = 3). At 2, 8 and 24 hours following plastering, blood was collected and serum was separated. The serum samples thus obtained were subjected to radioimmunoassay to determine the estradiol concentration.
- The results are shown in Figure 2. The estradiol preparations according to the present invention yielded good drug concentrations in blood and offered good sustained release. On the other hand, the rats to which the control estradiol preparation was plastered had very low drug concentrations in blood.
Claims (10)
- A sticky composition for medical use comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein the silicon atom is bound with a hydroxyl group or hydrolyzable group.
- A sticky composition according to claim 1, wherein said silicon-containing group is represented by the formula II:
- A sticky composition according to claim 2, wherein said hydrolyzable group represented by X is selected from the group consisting of a halogen atom, a hydrogen atom, an alkoxy group, an acyloxy group, a ketoximate group, an amino group, an amide group, an aminooxy group, a mercapto group and an alkenyloxy group.
- A sticky composition according to claim 3, wherein said alkoxy group is a methoxy group or ethoxy group.
- A sticky composition according to claim 2, wherein said monovalent hydrocarbon represented by R² is selected from the group consisting of an alkyl group, a cycloalkyl group, an aryl group and an aralkyl group.
- A sticky composition according to claim 5, wherein said monovalent hydrocarbon is a methyl group.
- A sticky composition according to claim 1, wherein the number of said silicon-containing group in the oxyalkylene polymer is not less than 1.
- A sticky composition according to claim 1, wherein the number-average molecular weight of said oxyalkylene polymer is 500 to 30000.
- A transdermal drug delivery preparation incorporating as a drug carrier a sticky composition according to anyone of claims 1 to 9.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28474590 | 1990-10-22 | ||
JP284745/90 | 1990-10-22 | ||
JP289259/90 | 1990-10-25 | ||
JP28925990 | 1990-10-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0482554A2 true EP0482554A2 (en) | 1992-04-29 |
EP0482554A3 EP0482554A3 (en) | 1993-02-03 |
EP0482554B1 EP0482554B1 (en) | 1995-09-20 |
Family
ID=26555594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91117920A Expired - Lifetime EP0482554B1 (en) | 1990-10-22 | 1991-10-21 | Transdermal Drug Delivery Preparation |
Country Status (4)
Country | Link |
---|---|
US (1) | US5556636A (en) |
EP (1) | EP0482554B1 (en) |
CA (1) | CA2053462A1 (en) |
DE (1) | DE69113205T2 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735024A1 (en) * | 1995-06-08 | 1996-12-13 | Sanofi Sa | Adhesive patches for cutaneous administration |
WO2004100926A3 (en) * | 2003-05-13 | 2005-02-24 | Medtronic Inc | Delivery of agents using hydrolyzable leaving groups |
US8668937B2 (en) | 2011-03-17 | 2014-03-11 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US9050248B2 (en) | 2002-05-31 | 2015-06-09 | Transdermal Biotechnology, Inc. | Methods of delivering stable topical drug compositions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9585931B2 (en) | 2013-03-13 | 2017-03-07 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9597400B2 (en) | 2013-03-13 | 2017-03-21 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9597401B2 (en) | 2013-03-13 | 2017-03-21 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
WO2017077284A1 (en) * | 2015-11-02 | 2017-05-11 | Medherant Limited | Drug delivery composition containing silyl polymers |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US10034914B2 (en) | 2013-03-13 | 2018-07-31 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US10226511B2 (en) | 2013-03-13 | 2019-03-12 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0891782B1 (en) * | 1997-07-17 | 2005-05-25 | Nitto Denko Corporation | Medical adhesive sheet and production thereof |
US6146656A (en) * | 1998-01-22 | 2000-11-14 | Nitto Denko Corporation | Percutaneous absorption preparation |
US20040086551A1 (en) * | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
US7651485B2 (en) * | 2002-11-27 | 2010-01-26 | Bristol-Myers Squibb Company | Ostomy pouch adhesives such as polysiloxanes that are resistant to stomal effluent |
BRPI0415652B8 (en) * | 2003-10-20 | 2021-07-27 | Hisamitsu Pharmaceutical Co | pressure sensitive adhesive composition |
JP5160217B2 (en) | 2004-03-12 | 2013-03-13 | ダウ・コーニング・コーポレイション | Method for preparing a silicone pressure sensitive adhesive for supplying hydrophilic drugs using a silicone polyether |
US20070202245A1 (en) * | 2004-04-08 | 2007-08-30 | Gantner David C | Silicone Skin Adhesive Gels With Enhanced Adhesion To Plastic |
CN101010065B (en) * | 2004-09-07 | 2012-02-29 | 陶氏康宁公司 | Silicone adhesive formulation containing an antiperspirant |
US7888422B2 (en) * | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
GB2443161B (en) * | 2006-10-28 | 2011-03-23 | Nupharm Lab Ltd | Clobetasol spray |
US7976951B2 (en) | 2006-11-14 | 2011-07-12 | Momentive Performance Materials Inc. | Laminate containing an adhesive-forming composition |
US7829116B2 (en) * | 2006-11-14 | 2010-11-09 | Momentive Performance Materials Inc. | Adhesive-forming composition and blend of adhesives obtained therefrom |
US9017301B2 (en) * | 2007-09-04 | 2015-04-28 | Mylan Technologies, Inc. | Transdermal drug delivery systems comprising a coated release liner |
DK2552245T3 (en) | 2010-03-26 | 2019-01-07 | Philip Morris Products Sa | INHIBITION OF SENSORY IRRITATION UNDER CONSUMPTION OF NON-SMOKABLE TOBACCO PRODUCTS |
US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
US11686094B2 (en) | 2013-03-15 | 2023-06-27 | Holcim Technology Ltd | Bonding adhesive and adhered roofing systems prepared using the same |
WO2017223173A1 (en) | 2016-06-21 | 2017-12-28 | Bridgestone Americas Tire Operations, Llc | Methods for treating inner liner surface, inner liners resulting therefrom and tires containing such inner liners |
BR112018077027B1 (en) | 2016-06-30 | 2023-03-14 | Bridgestone Americas Tire Operations, Llc | METHOD FOR TREATMENT OF A CURED INNER LINER FOR A TIRE; METHOD FOR PRODUCING A TIRE AND CURED TIRE |
WO2018112117A2 (en) | 2016-12-15 | 2018-06-21 | Bridgestone Americas Tire Operations, Llc | Methods for producing polymer-containing coatings upon cured inner liners, methods for producing tires containing such inner liners, and tires containing such inner liners |
US11697306B2 (en) | 2016-12-15 | 2023-07-11 | Bridgestone Americas Tire Operations, Llc | Sealant-containing tire and related processes |
DE102019120403A1 (en) * | 2019-07-29 | 2021-02-04 | Lts Lohmann Therapie-Systeme Ag | Process for the production of pressure-sensitive adhesives for use in a transdermal therapeutic system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0106330A1 (en) * | 1982-10-15 | 1984-04-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Pressure sensitive adhesive composition |
JPS6248785A (en) * | 1985-08-26 | 1987-03-03 | Sekisui Chem Co Ltd | Adhesive tape or film |
EP0276561A1 (en) * | 1986-12-24 | 1988-08-03 | Pfizer Inc. | Pharmaceutical tape compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6160771A (en) * | 1984-08-31 | 1986-03-28 | Kanegafuchi Chem Ind Co Ltd | Pressure-sensitive adhesive composition |
US4655767A (en) * | 1984-10-29 | 1987-04-07 | Dow Corning Corporation | Transdermal drug delivery devices with amine-resistant silicone adhesives |
JPH0623370B2 (en) * | 1986-03-25 | 1994-03-30 | 日本石油株式会社 | Adhesive composition |
JPH0751515B2 (en) * | 1986-09-10 | 1995-06-05 | 明治製菓株式会社 | Transdermal formulation |
-
1991
- 1991-10-15 CA CA002053462A patent/CA2053462A1/en not_active Abandoned
- 1991-10-21 EP EP91117920A patent/EP0482554B1/en not_active Expired - Lifetime
- 1991-10-21 DE DE69113205T patent/DE69113205T2/en not_active Expired - Fee Related
-
1994
- 1994-10-06 US US08/319,085 patent/US5556636A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0106330A1 (en) * | 1982-10-15 | 1984-04-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Pressure sensitive adhesive composition |
JPS6248785A (en) * | 1985-08-26 | 1987-03-03 | Sekisui Chem Co Ltd | Adhesive tape or film |
EP0276561A1 (en) * | 1986-12-24 | 1988-08-03 | Pfizer Inc. | Pharmaceutical tape compositions |
Non-Patent Citations (4)
Title |
---|
&JP-A-62048785 (SEKISUI CHEMICAL CO LTD) * |
CHEMICAL ABSTRACTS, vol. 105, no. 10, 8 September 1986, Columbus, Ohio, US; abstract no. 80198v, KINIMURA A. ET AL 'SURFACE PROTECTIVE ADHESIVE TAPES OR SHEETS' * |
CHEMICAL ABSTRACTS, vol. 107, no. 2, 13 July 1987, Columbus, Ohio, US; abstract no. 8601v, SHIRAISHI M. ET AL 'ADHESIVE TAPES' * |
CHEMICAL ABSTRACTS, vol. 107, no. 2, 13 July 1987, Columbus, Ohio, US; abstract no. 8601v, SHIRAISHI M. ET AL 'ADHESIVE TAPES' & JP-A-62048785 (SEKISUI CHEMICAL CO. LTD.) * |
Cited By (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735024A1 (en) * | 1995-06-08 | 1996-12-13 | Sanofi Sa | Adhesive patches for cutaneous administration |
US9050248B2 (en) | 2002-05-31 | 2015-06-09 | Transdermal Biotechnology, Inc. | Methods of delivering stable topical drug compositions |
US9060925B2 (en) | 2002-05-31 | 2015-06-23 | Transdermal Biotechnology, Inc. | Methods of delivering stable topical drug compositions |
WO2004100926A3 (en) * | 2003-05-13 | 2005-02-24 | Medtronic Inc | Delivery of agents using hydrolyzable leaving groups |
US7776351B2 (en) | 2003-05-13 | 2010-08-17 | Medtronic, Inc. | Moisture curable materials for delivery of agents, methods, and medical devices |
US8668937B2 (en) | 2011-03-17 | 2014-03-11 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
US9517179B2 (en) | 2011-03-17 | 2016-12-13 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
US9937202B2 (en) | 2011-03-17 | 2018-04-10 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems and methods of use thereof |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US10034897B2 (en) | 2012-09-19 | 2018-07-31 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US9480706B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US9198933B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US9198853B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US9198930B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US9198970B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US9198931B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US9198932B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US9198854B2 (en) | 2012-09-19 | 2015-12-01 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US9205043B2 (en) | 2012-09-19 | 2015-12-08 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US10034896B2 (en) | 2012-09-19 | 2018-07-31 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US10034898B2 (en) | 2012-09-19 | 2018-07-31 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US9295638B2 (en) | 2012-09-19 | 2016-03-29 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US9968635B2 (en) | 2012-09-19 | 2018-05-15 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US9968634B2 (en) | 2012-09-19 | 2018-05-15 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US9950004B2 (en) | 2012-09-19 | 2018-04-24 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US9844565B2 (en) | 2012-09-19 | 2017-12-19 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US9827266B2 (en) | 2012-09-19 | 2017-11-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US9795632B2 (en) | 2012-09-19 | 2017-10-24 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US9480711B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US9480708B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US9480705B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US9480710B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US9480707B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US9480709B2 (en) | 2012-09-19 | 2016-11-01 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US9498535B2 (en) | 2013-03-13 | 2016-11-22 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9844506B2 (en) | 2013-03-13 | 2017-12-19 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9439926B2 (en) | 2013-03-13 | 2016-09-13 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9585817B2 (en) | 2013-03-13 | 2017-03-07 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9585931B2 (en) | 2013-03-13 | 2017-03-07 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9585829B2 (en) | 2013-03-13 | 2017-03-07 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9597400B2 (en) | 2013-03-13 | 2017-03-21 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9597401B2 (en) | 2013-03-13 | 2017-03-21 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9636291B2 (en) | 2013-03-13 | 2017-05-02 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US10226511B2 (en) | 2013-03-13 | 2019-03-12 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9682102B2 (en) | 2013-03-13 | 2017-06-20 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9687504B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9694083B2 (en) | 2013-03-13 | 2017-07-04 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9694029B2 (en) | 2013-03-13 | 2017-07-04 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9700626B2 (en) | 2013-03-13 | 2017-07-11 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9717680B2 (en) | 2013-03-13 | 2017-08-01 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9757467B2 (en) | 2013-03-13 | 2017-09-12 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9827316B2 (en) | 2013-03-13 | 2017-11-28 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9480642B2 (en) | 2013-03-13 | 2016-11-01 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9872818B2 (en) | 2013-03-13 | 2018-01-23 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9913793B2 (en) | 2013-03-13 | 2018-03-13 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9931370B2 (en) | 2013-03-13 | 2018-04-03 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9937221B2 (en) | 2013-03-13 | 2018-04-10 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9943562B2 (en) | 2013-03-13 | 2018-04-17 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9956290B2 (en) | 2013-03-13 | 2018-05-01 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US10213457B2 (en) | 2013-03-13 | 2019-02-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US10028994B2 (en) | 2013-03-13 | 2018-07-24 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US10034914B2 (en) | 2013-03-13 | 2018-07-31 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US10034944B2 (en) | 2013-03-13 | 2018-07-31 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US10034828B2 (en) | 2013-03-13 | 2018-07-31 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US10064955B2 (en) | 2013-03-13 | 2018-09-04 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US10071117B2 (en) | 2013-03-13 | 2018-09-11 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US10080768B2 (en) | 2013-03-13 | 2018-09-25 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US10155048B2 (en) | 2013-03-13 | 2018-12-18 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US10188603B2 (en) | 2013-03-13 | 2019-01-29 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
CN108289831A (en) * | 2015-11-02 | 2018-07-17 | 海伦特医药有限公司 | Drug delivery composition containing silyl polymer |
WO2017077284A1 (en) * | 2015-11-02 | 2017-05-11 | Medherant Limited | Drug delivery composition containing silyl polymers |
US11160764B2 (en) | 2015-11-02 | 2021-11-02 | Medherant Limited | Drug delivery composition containing silyl polymers |
CN108289831B (en) * | 2015-11-02 | 2021-11-19 | 海伦特医药有限公司 | Drug delivery compositions containing silyl polymers |
Also Published As
Publication number | Publication date |
---|---|
DE69113205D1 (en) | 1995-10-26 |
DE69113205T2 (en) | 1996-02-22 |
US5556636A (en) | 1996-09-17 |
EP0482554A3 (en) | 1993-02-03 |
EP0482554B1 (en) | 1995-09-20 |
CA2053462A1 (en) | 1992-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0482554B1 (en) | Transdermal Drug Delivery Preparation | |
JP2573638B2 (en) | Percutaneous fertility regulation systems and methods | |
FI107708B (en) | Process for preparing a matrix for use in a drug delivery device | |
US5230896A (en) | Transdermal nicotine delivery system | |
DE69806988T2 (en) | Process for the production of controlled release agents | |
JP3046346B2 (en) | External preparation base or auxiliary agent and human or animal external preparation containing it | |
JPH02500741A (en) | Transdermal administration unit and method of administration for narcotic analgesics and antagonists | |
IE60569B1 (en) | A medicated dressing | |
JPH04507256A (en) | Biphasic transdermal drug delivery device | |
EP0269696A1 (en) | Transdermal absorption dosage unit for estradiol and other estrogenic steroids. | |
JPH05194201A (en) | Pressure-sensitive silicone adhesive composition for use in percutaneous drug administration apparatus and related medical appliance | |
KR20120026507A (en) | Silicone acrylic hybrid polymer-based adhesives | |
US4954343A (en) | Dermal pharmaceutical preparations | |
CA2140468C (en) | Percutaneous administration tape preparation | |
KR20040030408A (en) | Non-reactive adhesive useful in transdermal drug delivery systems | |
JPH07330591A (en) | Percutaneously absorbable pharmaceutical preparation | |
JPH0152362B2 (en) | ||
JPH046164B2 (en) | ||
JPH0723306B2 (en) | New patch preparation | |
JPH05936A (en) | Percutaneous absorption preparation | |
JP6773897B2 (en) | Patch | |
JP3240496B2 (en) | Transdermal formulation | |
JPH05286851A (en) | Application agent for treating disease | |
JPH06256173A (en) | Medical application agent | |
JPH05255077A (en) | Anti-inflammatory analgesic plaster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): CH DE FR GB LI |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): CH DE FR GB LI |
|
17P | Request for examination filed |
Effective date: 19930312 |
|
17Q | First examination report despatched |
Effective date: 19940429 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE FR GB LI |
|
REF | Corresponds to: |
Ref document number: 69113205 Country of ref document: DE Date of ref document: 19951026 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19971009 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19971013 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19971106 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19981021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19981031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19981031 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19981021 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990630 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20001016 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020702 |